Melinta Therapeutics

OverviewSuggest Edit

Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections. Its four marketed products include Baxdela (delafloxacin), Vabomere (meropenem and vaborbactam), Orbactiv (oritavancin), and Minocin (minocycline) for injection. The Company also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market.


Latest Updates

Employees (est.) (Jun 2019)261(-1%)
Share Price (Oct 2019)$4.4 (-4%)

Key People/Management at Melinta Therapeutics

John Johnson

John Johnson

Director, CEO
Sue Cammarata

Sue Cammarata

Chief Medical Officer
Peter Milligan

Peter Milligan

Show more

Melinta Therapeutics Office Locations

Melinta Therapeutics has an office in New Haven
New Haven, US
300 George Street Suite 301
Show all (1)

Melinta Therapeutics Financials and Metrics

Melinta Therapeutics Revenue

Market capitalization (17-Oct-2019)


Closing stock price (17-Oct-2019)

Melinta Therapeutics's current market capitalization is $60.2 m.
Show all financial metrics

Melinta Therapeutics Online and Social Media Presence

Embed Graph

Melinta Therapeutics News and Updates

Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting

~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~

Thinking about buying stock in Beyond Meat, DGSE, Interpace Diagnostics, Melinta Therapeutics, or Oracle?

NEW YORK, June 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BYND, DGSE, IDXG, MLNT, and ORCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia

~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~

Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting

MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced today that it will present data on its portfolio, includin…

Melinta Therapeutics Frequently Asked Questions

  • When was Melinta Therapeutics founded?

    Melinta Therapeutics was founded in 2000.

  • Who are Melinta Therapeutics key executives?

    Melinta Therapeutics's key executives are John Johnson, Sue Cammarata and Peter Milligan.

  • How many employees does Melinta Therapeutics have?

    Melinta Therapeutics has 261 employees.

  • Who are Melinta Therapeutics competitors?

    Competitors of Melinta Therapeutics include Cardiorentis, Genoa Pharmaceuticals and GBT (Global Blood Therapeutics).

  • Where are Melinta Therapeutics offices?

    Melinta Therapeutics has an office in New Haven.

  • How many offices does Melinta Therapeutics have?

    Melinta Therapeutics has 1 office.